Clinical Trial Update: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carfilzomib with lenalidomide and dexamethasone for mantle cell lymphoma that relapsed after or is intolerant to BTK inhibitors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• carfilzomib + lenalidomide and dexamethasone

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: UNKNOWN